Stratified Treatment in Pediatric Anaplastic Large Cell Lymphoma: Result of a Prospective Open-Label...

Area of Science:

• Pediatric Oncology
• Hematology
• Lymphoma Research

Background:

• Standardized risk stratification for pediatric anaplastic large cell lymphoma (ALCL) is lacking.
• Accurate risk assessment is crucial for tailoring treatment and improving outcomes in pediatric ALCL.

Purpose of the Study:

• To establish a novel, feasible risk stratification system for pediatric anaplastic large cell lymphoma (ALCL).
• To incorporate new risk factors into the existing stratification to enhance its clinical utility.

Main Methods:

• Patients were stratified based on the non-Hodgkin's lymphoma Berlin-Frankfurt-Munster 95 (NHL-BFM-95) protocol, including minimal disseminated disease (MDD), high-risk tumor sites, and small cell/lymphohistiocytic (SC/LH) subtype.
• Treatment involved a modified NHL-BFM-95 protocol with either an anaplastic lymphoma kinase inhibitor or vinblastine (VBL).

Main Results:

• The study included 136 pediatric ALCL patients; 3-year event-free survival (EFS) was 77.7%.
• Risk groups (R1, R2, R3) showed distinct 3-year EFS rates: 100%, 89.5%, and 67.9%, respectively.
• Poor prognostic indicators included MDD, stage IV disease, SC/LH subtype, and high-risk sites, with significantly lower EFS rates.

Conclusions:

• The study confirms MDD, high-risk sites, and SC/LH subtype as poor prognostic factors in pediatric ALCL.
• Patients with SC/LH lymphoma and MDD require further investigation for optimized treatment strategies.